Fei F, Natkunam Y, Zehnder JL et al (2022) Diagnostic impact of next-generation sequencing panels for lymphoproliferative neoplasms on small-volume biopsies. Am J Clin Pathol 158:345–361. https://doi.org/10.1093/ajcp/aqac045

Article  CAS  PubMed  Google Scholar 

Ma X, Liu Y, Liu Y et al (2018) Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. Nature 555:371–376. https://doi.org/10.1038/nature25795

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fu JF, Hsu HC, Shih LY (2005) MLL is fused to EBI (MAPREI), which encodes a microtubule-associated protein, in a patient with acute lymphoblastic leukemia. Genes Chromosom Cancer 43:206–210. https://doi.org/10.1002/gcc.20174

Article  CAS  PubMed  Google Scholar 

Choi J, Goh G, Walradt T et al (2015) Genomic landscape of cutaneous T cell lymphoma. Nat Genet 47:1011–1019. https://doi.org/10.1038/ng.3356

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kießling MK, Oberholzer PA, Mondal C et al (2011) High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade. Blood 117:2433–2440. https://doi.org/10.1182/blood-2010-09-305128

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yanagi T, Nishihara H, Fujii K et al (2017) Comprehensive cancer-related gene analysis reveals that active KRAS mutation is a prognostic mutation in mycosis fungoides. J Dermatol Sci 88:367–370. https://doi.org/10.1016/j.jdermsci.2017.07.013

Article  CAS  PubMed  Google Scholar 

Park J, Yang J, Wenzel AT et al (2017) Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E). Blood 130:1430–1440. https://doi.org/10.1182/blood-2017-02-768234

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vaqué JP, Gómez-López G, Monsálvez V et al (2014) PLCG1 mutations in cutaneous T-cell lymphomas. Blood 123:2034–2043. https://doi.org/10.1182/blood-2013-05-504308

Article  CAS  PubMed  Google Scholar 

Argyropoulos KV, Pulitzer M, Maura F et al (2020) Targeted genomic analysis of cutaneous T cell lymphomas identifies a subset with aggressive clinicopathological features. Blood Cancer J 10:116. https://doi.org/10.1038/s41408-020-00380-5

Article  PubMed  PubMed Central  Google Scholar 

Meyer C, Burmeister T, Gröger D et al (2018) The MLL recombinome of acute leukemias in 2017. Leukemia 32:273–284. https://doi.org/10.1038/leu.2017.213

Article  CAS  PubMed  Google Scholar 

Rao RC, Dou Y (2015) Hijacked in cancer: the KMT2 (MLL) family of methyltransferases. Nat Rev Cancer 15:334–346. https://doi.org/10.1038/nrc3929

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yu BD, Hess JL, Horning SE et al (1995) Altered Hox expression and segmental identity in Mll-mutant mice. Nature 378:505–508. https://doi.org/10.1038/378505a0

Article  CAS  PubMed  Google Scholar 

Meyer C, Burmeister T, Gröger D et al (2020) Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/KMT2A. Proc Natl Acad Sci USA 117:26340–26346. https://doi.org/10.1073/pnas.2014732117

Article  CAS  Google Scholar 

Issa GC, Aldoss I, DiPersio J et al (2023) The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature. https://doi.org/10.1038/s41586-023-05812-3

Gui Y, Guo G, Huang Y et al (2011) Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet 43:875–878. https://doi.org/10.1038/ng.907

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ji M-M, Huang Y-H, Huang J-Y et al (2018) Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified. Haematologica 103:679–687. https://doi.org/10.3324/haematol.2017.182444

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stomper J, Rotondo JC, Greve G, Lübbert M (2021) Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies. Leukemia 35:1873–1889

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ball BJ, Arslan S, Koller P et al (2022) Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML). Leuk. Lymphoma 63:3232–3236

Article  CAS  PubMed  Google Scholar 

Krivtsov AV, Armstrong SA (2007) MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 7:823–833

Article  CAS  PubMed  Google Scholar